General SurgeryNCT02664142
BIS Monitoring of the Depth of Anaesthesia in Children
A study testing BIS Group, Non-BIS Group and Anaesthetics in people with General Surgery and Anaesthesia, run by University Hospital Ostrava at 1 site in Czechia.
Trial summary
General anaesthesia (GA) is, according to many definitions, the greatest gift presented to the medical art (S. B. Nuland). One of the aims of GA is to achieve the optimal depth of anaesthesia and rapid emergence from general anaesthesia. Read more about this study
- Who is it for?
- Ages 15 days to 15 years
- Conditions the study is for
- General Surgery, Anaesthesia
- What is being tested?
- BIS Group, Non-BIS Group and Anaesthetics
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 220 participants
- Where
- 1 siteCzechia
- Study dates
- Jun 2015to Nov 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 days to 15 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- appropriate age
- informed consent form signed by both parents (according to national legislation)
- need to undergo a procedure in general anaesthesia
- ASA I classification
Who cannot join
- non-signing of the informed consent form by both parents
- ASA classification higher than I
Trial locations and contacts
1 site in 1 country.
Czechia1 site
University Hospital Ostrava
Ostrava, Moravian-Silesian Region, 70852
About this study
Official title: Monitoring the Depth of Anaesthesia in Children in the Course of a Surgical Procedure Using the BIS Monitor - Prospective Randomized Study
General anaesthesia (GA) is, according to many definitions, the greatest gift presented to the medical art (S. B. Nuland). One of the aims of GA is to achieve the optimal depth of anaesthesia and rapid emergence from general anaesthesia. In order to achieve this goal, it is necessary to observe the clinical condition of the patient, and at the same time monitor the patient's overall condition. With the currently available options of GA management (e.g. use of intravenous anaesthetics, strong analgesics and modern volatile anaesthetics, in combination with various methods of topical anaesthesia) the importance of methods measuring the depth of GA increases. The depth of GA may be defined as a continuous progressive decreasing of the central nervous system, together with a decreased reactivity to stimuli. In the course of GA, perioperative awareness is detected in 0.1-0.2% of cases. Awakening during a surgical procedure may result in significant psychological complications (e.g. post-traumatic stress disorder), and the patient may suffer from a serious long-time disorder.
Read the detailed description
In order to prevent, or minimize the perioperative awareness, it is possible to utilize two different methods of depth of anaesthesia monitoring. The options may be divided into two basic groups: A/ The use of clinical monitoring and other methods (apart from CNS), and B/ Methods based on monitoring of the electrical activity of the brain. In the first group, it is possible to list the following options: 1. clinical assessment (Evans's score), 2. skin conductance, 3. isolated method of measurement at the forearm, 4. spontaneous superficial electromyogram (SEMG), 5. lower oesophageal contractility, and 6. various hearth rate. The possibilities of depth of GA monitoring using the scanning of electrical brain activity may be further subdivided into two groups: a/ methods based on EEG, and b/ methods assessing evoked potentials. In the group of methods based on EEG, the following devices may be used to monitor the depth of GA in practice:
a/ BIS monitor, b/ E-Entropy, c/ Narcotrend, and d/ SedLine Sedation Monitor. In the second group using evoked potentials it is possible to utilize monitors measuring electrical activity in certain areas of the brain, in relation to stimulation of specific sensory nerve pathways: a/ somatosensory, b/ visual, and c/ auditive evoked potentials.
Aims of the Study:
Null hypothesis: The use of depth of general anaesthesia monitoring in children in the course of a surgical procedure does not affect the number of post-operative complications related to the depth of GA, does not shorten the period of emergence from GA, does not decrease the amount of inhalation anaesthetics used, and does not decrease the amount of opioids used.
Primary aim: To test, whether the administration of anaesthesia in children in the course of a surgical procedure with the depth of general anaesthesia monitoring with the BIS monitor results in a decrease in the number of complications related to inappropriate depth of GA.
Secondary aim: To verify, whether the administration of anaesthesia in children in the course of a surgical procedure with the depth of general anaesthesia monitoring with the BIS monitor:
- results in a shortening of the emergence from general anaesthesia
- results in a decrease in the amount of inhalation anaesthetic used
- results in a decrease in the amount of analgesics used
Tertiary aim: To verify, whether the administration of general anaesthesia in children in the course of a surgical procedure with the depth of general anaesthesia monitoring with the BIS monitor:
a/results in a decrease of early post-operative complications at the recovery room.
Study design:
Procedure to achieve the study aims The study is a prospective, interventional study, performed at the Anaesthesiology-Resuscitation Department of the University Hospital Ostrava. The study has been approved by the Head of the Department, prof. Pavel Ševčík, MD, CSc. Furthermore, the study has been approved by the Ethics Committee of the University Hospital Ostrava and is in compliance with the principles of the Declaration of Helsinki. Informed consent will be obtained for every paediatric patient, the Informed consent form has also been approved by the Ethics Committee, and will be signed by both parents.
The study group will include paediatric patients at the age from 28 days to 15 years of age (including), ASA I classification.
Interventional arm of the study will be characterized by the BIS monitoring and management of the hypnotic component of general anaesthesia towards the values of BIS 40-60.
Conventional arm of the study will be performed without the depth of anaesthesia monitoring (however, the BIS value will be recorded by an independent participant), and management of the hypnotic component of general anaesthesia according to MAC value appropriate for the age of the child.
Each study arm will include the total of 100 paediatric study subjects. Randomization will be performed by the envelope method.
Definition of terms
- BIS group: group of patients, in whom the hypnotic component of GA will be managed towards the value of BIS 40-60.
- Non-BIS group: group of patients, in whom the hypnotic component of GA will be managed towards the MAC value appropriate for the age of the child. Depth of GA will be also monitored with the BIS monitor, however, the BIS value will be unknown to the investigator.
- Period of emergence from anaesthesia: time interval from the moment of setting the zero concentration of inhalation anaesthetics on the vaporizer to the moment when the child manifests the signs of complete awareness: spontaneous ventilation, spontaneous motility, rising of the head, clasping of the hand, or crying.
- Consumption of inhalation anaesthetic: consumption of inhalation anaesthetic will be measured in two follow-up time phases of GA:
- Phase 1: from the moment when administration of the inhalation anaesthetic is initiated to the moment when breathing passageways are secured (LM, OTI). This phase of GA is characterized with a higher concentration of the inhalation anaesthetic and standard flows: O2, AIR in proportion of 2:2 l/min,
- Phase 2: continues after Phase 1, from the moment when breathing passageways are secured to the moment, when the zero value is set on the vaporizer. This phase of GA is characterized with gas flows: O2, AIR in proportion of 0.5:0.5 l/min.
- Consumption of analgesics: the amount of analgesics used during GA
- Early post-operative complications (assessed in the recovery room): the need of re-intubation, need to apply antidotes, laryngospasm, bronchospasm, hyperalgesia (pain assessment according to standard scales), vomiting
- Emergence from GA (Phase 3): continues after Phase 2, from the moment when the zero value is set on the vaporizer to the moment of LM or intubation cannula removal.
5.2.2. Protocol of GA management in the "BIS group": BIS monitor will be used during the GA monitoring, the BIS value will be known to the anaesthetist (investigator)
- GA induction (Phase 1):
- inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or
- intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)
- anaesthesia (Phase 2, Phase 3):
- hypnotic component: titration of Sevorane concentration, with the aim of achieving the BIS values of 40-60%, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)
- analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)
- relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) 5.2.3. Protocol of GA management in the "Non-BIS group" BIS monitor will be used during the GA monitoring, however the BIS value will not be known to the anaesthetist (investigator)
- GA induction (Phase 1):
- inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or
- intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)
- anaesthesia (Phase 2, Phase 3):
- hypnotic component: titration of Sevorane concentration, with the aim of achieving the MAC value appropriate for the age of the child, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)
- analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)
- relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg)
Assessment:
The following parameters will be observed in the "BIS group" and the "Non-BIS group":
- occurrence of perioperative complications
- period of emergence from GA
- consumption of opioids
- consumption of inhalation anaesthetic
- occurrence of early post-operative complications at the recovery room
- BIS value
Statistical processing:
The obtained statistical data will be processed using statistical methods and presented in the form of tables and charts.
- Conditions
- General Surgery, Anaesthesia
- Being tested
- BIS Group, Non-BIS Group, Anaesthetics
- Keywords
- General Surgery, Child, Anaesthesia, Depth of anaesthesia, BIS monitoring
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BIS GroupProcedure or surgery
BIS monitoring will be used in the BIS Group patients. The BIS value will be known to the anaesthetist, who will be able to act accordingly.
Non-BIS GroupProcedure or surgery
BIS monitoring will be used in the Non-BIS Group patients. The BIS value will NOT be known to the anaesthetist and will be observed by a trained co-investigator, with subsequent evaluation.
AnaestheticsDrug
Anaesthetics will be administered in both experimental groups, in order to maintain the required general anaesthesia.
| Study group | Role | What they receive |
|---|---|---|
| BIS Group | Experimental | BIS monitor will be used during the GA monitoring, the BIS value will be known to the anaesthetist (investigator)
* GA induction (Phase 1):
1. inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or
2. intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)
* anaesthesia (Phase 2, Phase 3):
1. hypnotic component: titration of Sevorane concentration, with the aim of achieving the BIS values of 40-60%, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)
2. analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)
3. relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) Patients in this group will be administered anaesthetic, in order to achieve and maintain the required general anaesthesia. Receives: Procedure: BIS Group; Drug: Anaesthetics |
| Non-BIS Group | Experimental | BIS monitor will be used during the GA monitoring, however the BIS value will not be known to the anaesthetist (investigator)
* GA induction (Phase 1):
1. inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or
2. intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)
* anaesthesia (Phase 2, Phase 3):
1. hypnotic component: titration of Sevorane concentration, with the aim of achieving the MAC value appropriate for the age of the child, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)
2. analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)
3. relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) Patients in this group will be administered anaesthetic, in order to achieve and maintain the required general anaesthesia. Receives: Procedure: Non-BIS Group; Drug: Anaesthetics |
What is being measured
The primary outcome is the main question the study is designed to answer.
Occurrence of perioperative complications
The occurrence of perioperative complications due to inappropriate depth of general anaesthesia will be observed.
Measured: 24 months
Secondary outcomes (3)
Shortening of the emergence from general anaesthesia
The time of emergence from general anaesthesia will be measured and compared in both groups.
Measured: 24 months
Decrease in the amount of inhalation anaesthetic used
The decrease in the amount of inhalation anaesthetic used will be measured and compared in both groups.
Measured: 24 months
Decrease in the amount of analgesics used
The decrease in the amount of analgesics used will be measured and compared in both groups.
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2016 (estimated)
- Study startJun 2015
- Primary completionSep 2017
- Study completionNov 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for General SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 220 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital Ostrava
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jan Divak, MD, Principal investigator, University Hospital Ostrava
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02664142
- Sponsor's protocol ID
- FNO-KARIM-3
- Status last verified
- Mar 2018
- First submitted
- 18 Jan 2016
- Last updated
- 23 Mar 2018
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Mar 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Monitoring the Depth of Anaesthesia in Children in the Course of a Surgical Procedure Using the BIS Monitor - Prospective Randomized Study
- ClinicalTrials.gov ID
- NCT02664142
- Acronym / sponsor ID
- FNO-KARIM-3
- Conditions
- General Surgery, Anaesthesia
- Keywords
- General Surgery, Child, Anaesthesia, Depth of anaesthesia, BIS monitoring
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 220 participants (actual)
- Lead sponsor
- University Hospital OstravaUniversity, hospital or other
- Study start
- Jun 2015 (actual)
- Primary completion
- Sep 2017 (actual)
- Study completion
- Nov 2017 (actual)
- First posted
- 26 Jan 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
General anaesthesia (GA) is, according to many definitions, the greatest gift presented to the medical art (S. B. Nuland). One of the aims of GA is to achieve the optimal depth of anaesthesia and rapid emergence from general anaesthesia. In order to achieve this goal, it is necessary to observe the clinical condition of the patient, and at the same time monitor the patient's overall condition. With the currently available options of GA management (e.g. use of intravenous anaesthetics, strong analgesics and modern volatile anaesthetics, in combination with various methods of topical anaesthesia) the importance of methods measuring the depth of GA increases. The depth of GA may be defined as a continuous progressive decreasing of the central nervous system, together with a decreased reactivity to stimuli. In the course of GA, perioperative awareness is detected in 0.1-0.2% of cases. Awakening during a surgical procedure may result in significant psychological complications (e.g. post-traumatic stress disorder), and the patient may suffer from a serious long-time disorder.
Detailed description
In order to prevent, or minimize the perioperative awareness, it is possible to utilize two different methods of depth of anaesthesia monitoring. The options may be divided into two basic groups: A/ The use of clinical monitoring and other methods (apart from CNS), and B/ Methods based on monitoring of the electrical activity of the brain. In the first group, it is possible to list the following options: 1. clinical assessment (Evans's score), 2. skin conductance, 3. isolated method of measurement at the forearm, 4. spontaneous superficial electromyogram (SEMG), 5. lower oesophageal contractility, and 6. various hearth rate. The possibilities of depth of GA monitoring using the scanning of electrical brain activity may be further subdivided into two groups: a/ methods based on EEG, and b/ methods assessing evoked potentials. In the group of methods based on EEG, the following devices may be used to monitor the depth of GA in practice:
a/ BIS monitor, b/ E-Entropy, c/ Narcotrend, and d/ SedLine Sedation Monitor. In the second group using evoked potentials it is possible to utilize monitors measuring electrical activity in certain areas of the brain, in relation to stimulation of specific sensory nerve pathways: a/ somatosensory, b/ visual, and c/ auditive evoked potentials.
Aims of the Study:
Null hypothesis: The use of depth of general anaesthesia monitoring in children in the course of a surgical procedure does not affect the number of post-operative complications related to the depth of GA, does not shorten the period of emergence from GA, does not decrease the amount of inhalation anaesthetics used, and does not decrease the amount of opioids used.
Primary aim: To test, whether the administration of anaesthesia in children in the course of a surgical procedure with the depth of general anaesthesia monitoring with the BIS monitor results in a decrease in the number of complications related to inappropriate depth of GA.
Secondary aim: To verify, whether the administration of anaesthesia in children in the course of a surgical procedure with the depth of general anaesthesia monitoring with the BIS monitor:
- results in a shortening of the emergence from general anaesthesia
- results in a decrease in the amount of inhalation anaesthetic used
- results in a decrease in the amount of analgesics used
Tertiary aim: To verify, whether the administration of general anaesthesia in children in the course of a surgical procedure with the depth of general anaesthesia monitoring with the BIS monitor:
a/results in a decrease of early post-operative complications at the recovery room.
Study design:
Procedure to achieve the study aims The study is a prospective, interventional study, performed at the Anaesthesiology-Resuscitation Department of the University Hospital Ostrava. The study has been approved by the Head of the Department, prof. Pavel Ševčík, MD, CSc. Furthermore, the study has been approved by the Ethics Committee of the University Hospital Ostrava and is in compliance with the principles of the Declaration of Helsinki. Informed consent will be obtained for every paediatric patient, the Informed consent form has also been approved by the Ethics Committee, and will be signed by both parents.
The study group will include paediatric patients at the age from 28 days to 15 years of age (including), ASA I classification.
Interventional arm of the study will be characterized by the BIS monitoring and management of the hypnotic component of general anaesthesia towards the values of BIS 40-60.
Conventional arm of the study will be performed without the depth of anaesthesia monitoring (however, the BIS value will be recorded by an independent participant), and management of the hypnotic component of general anaesthesia according to MAC value appropriate for the age of the child.
Each study arm will include the total of 100 paediatric study subjects. Randomization will be performed by the envelope method.
Definition of terms
- BIS group: group of patients, in whom the hypnotic component of GA will be managed towards the value of BIS 40-60.
- Non-BIS group: group of patients, in whom the hypnotic component of GA will be managed towards the MAC value appropriate for the age of the child. Depth of GA will be also monitored with the BIS monitor, however, the BIS value will be unknown to the investigator.
- Period of emergence from anaesthesia: time interval from the moment of setting the zero concentration of inhalation anaesthetics on the vaporizer to the moment when the child manifests the signs of complete awareness: spontaneous ventilation, spontaneous motility, rising of the head, clasping of the hand, or crying.
- Consumption of inhalation anaesthetic: consumption of inhalation anaesthetic will be measured in two follow-up time phases of GA:
- Phase 1: from the moment when administration of the inhalation anaesthetic is initiated to the moment when breathing passageways are secured (LM, OTI). This phase of GA is characterized with a higher concentration of the inhalation anaesthetic and standard flows: O2, AIR in proportion of 2:2 l/min,
- Phase 2: continues after Phase 1, from the moment when breathing passageways are secured to the moment, when the zero value is set on the vaporizer. This phase of GA is characterized with gas flows: O2, AIR in proportion of 0.5:0.5 l/min.
- Consumption of analgesics: the amount of analgesics used during GA
- Early post-operative complications (assessed in the recovery room): the need of re-intubation, need to apply antidotes, laryngospasm, bronchospasm, hyperalgesia (pain assessment according to standard scales), vomiting
- Emergence from GA (Phase 3): continues after Phase 2, from the moment when the zero value is set on the vaporizer to the moment of LM or intubation cannula removal.
5.2.2. Protocol of GA management in the "BIS group": BIS monitor will be used during the GA monitoring, the BIS value will be known to the anaesthetist (investigator)
- GA induction (Phase 1):
- inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or
- intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)
- anaesthesia (Phase 2, Phase 3):
- hypnotic component: titration of Sevorane concentration, with the aim of achieving the BIS values of 40-60%, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)
- analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)
- relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) 5.2.3. Protocol of GA management in the "Non-BIS group" BIS monitor will be used during the GA monitoring, however the BIS value will not be known to the anaesthetist (investigator)
- GA induction (Phase 1):
- inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or
- intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)
- anaesthesia (Phase 2, Phase 3):
- hypnotic component: titration of Sevorane concentration, with the aim of achieving the MAC value appropriate for the age of the child, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)
- analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)
- relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg)
Assessment:
The following parameters will be observed in the "BIS group" and the "Non-BIS group":
- occurrence of perioperative complications
- period of emergence from GA
- consumption of opioids
- consumption of inhalation anaesthetic
- occurrence of early post-operative complications at the recovery room
- BIS value
Statistical processing:
The obtained statistical data will be processed using statistical methods and presented in the form of tables and charts.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| BIS Group | Experimental | Procedure: BIS Group, Drug: AnaestheticsBIS monitor will be used during the GA monitoring, the BIS value will be known to the anaesthetist (investigator) * GA induction (Phase 1): 1. inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or 2. intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg) * anaesthesia (Phase 2, Phase 3): 1. hypnotic component: titration of Sevorane concentration, with the aim of achieving the BIS values of 40-60%, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows) 2. analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min) 3. relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) Patients in this group will be administered anaesthetic, in order to achieve and maintain the required general anaesthesia. |
| Non-BIS Group | Experimental | Procedure: Non-BIS Group, Drug: AnaestheticsBIS monitor will be used during the GA monitoring, however the BIS value will not be known to the anaesthetist (investigator) * GA induction (Phase 1): 1. inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or 2. intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg) * anaesthesia (Phase 2, Phase 3): 1. hypnotic component: titration of Sevorane concentration, with the aim of achieving the MAC value appropriate for the age of the child, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows) 2. analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min) 3. relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) Patients in this group will be administered anaesthetic, in order to achieve and maintain the required general anaesthesia. |
Who may qualify
- Ages
- 15 days to 15 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- appropriate age
- informed consent form signed by both parents (according to national legislation)
- need to undergo a procedure in general anaesthesia
- ASA I classification
Key exclusion criteria (2 listed)
- non-signing of the informed consent form by both parents
- ASA classification higher than I
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BIS GroupBIS monitoring will be used in the BIS Group patients. The BIS value will be known to the anaesthetist, who will be able to act accordingly. | Procedure or surgery | BIS Group |
| Non-BIS GroupBIS monitoring will be used in the Non-BIS Group patients. The BIS value will NOT be known to the anaesthetist and will be observed by a trained co-investigator, with subsequent evaluation. | Procedure or surgery | Non-BIS Group |
| AnaestheticsAnaesthetics will be administered in both experimental groups, in order to maintain the required general anaesthesia. | Drug | BIS Group, Non-BIS Group |
Primary outcome
Occurrence of perioperative complications
Time frame: 24 months
The occurrence of perioperative complications due to inappropriate depth of general anaesthesia will be observed.
3 secondary outcomes
Shortening of the emergence from general anaesthesia
Time frame: 24 months
Decrease in the amount of inhalation anaesthetic used
Time frame: 24 months
Decrease in the amount of analgesics used
Time frame: 24 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Mar 2018.
- Individual participant dataSharing planned: No
Related trials for General Surgery
RecruitingObservational study
Comparison of Hemodynamic Responses During Anesthesia Induction Using Eleveld and Schnider
Spinal (Fusion) Surgery, Total Intravenous Anesthesia
RecruitingPhase 1
Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia
Renal Failure Congenital, Congenital Renal Anomaly Nos
RecruitingPhase 2
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
Not yet recruiting
Augmented-Reality ICG Fluorescence Second-Look for Residual Nodal Disease After Axillary Dissection in Breast Cancer
Breast Cancer, Breast Neoplasms
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jan Divak, MD principal investigator
University Hospital Ostrava
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing BIS Group, Non-BIS Group and Anaesthetics in people with General Surgery and Anaesthesia, run by University Hospital Ostrava at 1 site in Czechia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Occurrence of perioperative complications (time frame: 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Mar 2018.